Hodgkin lymphoma. ASCO, EHA and ASH 2020 news
The review shows the most interesting and promising studies presented at major international conferences of the American Society of Clinical Oncology, the European Hematology Association, and the American Society of Hematology in 2020. The main aim of the therapy for Hodgkin lymphoma (HL), which hav...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/772208517a7b4f479036d2979c08965d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:772208517a7b4f479036d2979c08965d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:772208517a7b4f479036d2979c08965d2021-11-30T16:55:01ZHodgkin lymphoma. ASCO, EHA and ASH 2020 news1815-14341815-144210.26442/18151434.2021.1.200746https://doaj.org/article/772208517a7b4f479036d2979c08965d2021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70507/51424https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442The review shows the most interesting and promising studies presented at major international conferences of the American Society of Clinical Oncology, the European Hematology Association, and the American Society of Hematology in 2020. The main aim of the therapy for Hodgkin lymphoma (HL), which have been formulated over the past 20 years, is the highly effective therapy and high quality of life, and the main possibility to solve this task is positron emission tomography (PET). The studies presented at conferences this year have shown that PET-adapted therapy has become the basis of modern HL therapy. The second equally interesting direction presented at the conferences this year is the widespread use of targeted (brentuximab vedotin) therapy and immunotherapy (nivolumab, pembrolizumab) in combination with standard chemotherapy not only in patients with relapsed/refractory HL, but also as first-line therapy, including the patients of an elderly section. The combination of brentuximab vedotin and immunotherapy during all lines of HL treatment, as well as brentuximab vedotin and immunotherapy consolidation after high-dose chemotherapy and autologous stem cell transplantation are another direction to improve the efficacy of therapy in patients with HL.Elena A. DeminaIP Habib O.N.articlehodgkin lymphomachemotherapyimmunotherapybrentuximab vedotinnivolumabpembrolizumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 185-191 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
hodgkin lymphoma chemotherapy immunotherapy brentuximab vedotin nivolumab pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
hodgkin lymphoma chemotherapy immunotherapy brentuximab vedotin nivolumab pembrolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Elena A. Demina Hodgkin lymphoma. ASCO, EHA and ASH 2020 news |
| description |
The review shows the most interesting and promising studies presented at major international conferences of the American Society of Clinical Oncology, the European Hematology Association, and the American Society of Hematology in 2020. The main aim of the therapy for Hodgkin lymphoma (HL), which have been formulated over the past 20 years, is the highly effective therapy and high quality of life, and the main possibility to solve this task is positron emission tomography (PET). The studies presented at conferences this year have shown that PET-adapted therapy has become the basis of modern HL therapy. The second equally interesting direction presented at the conferences this year is the widespread use of targeted (brentuximab vedotin) therapy and immunotherapy (nivolumab, pembrolizumab) in combination with standard chemotherapy not only in patients with relapsed/refractory HL, but also as first-line therapy, including the patients of an elderly section. The combination of brentuximab vedotin and immunotherapy during all lines of HL treatment, as well as brentuximab vedotin and immunotherapy consolidation after high-dose chemotherapy and autologous stem cell transplantation are another direction to improve the efficacy of therapy in patients with HL. |
| format |
article |
| author |
Elena A. Demina |
| author_facet |
Elena A. Demina |
| author_sort |
Elena A. Demina |
| title |
Hodgkin lymphoma. ASCO, EHA and ASH 2020 news |
| title_short |
Hodgkin lymphoma. ASCO, EHA and ASH 2020 news |
| title_full |
Hodgkin lymphoma. ASCO, EHA and ASH 2020 news |
| title_fullStr |
Hodgkin lymphoma. ASCO, EHA and ASH 2020 news |
| title_full_unstemmed |
Hodgkin lymphoma. ASCO, EHA and ASH 2020 news |
| title_sort |
hodgkin lymphoma. asco, eha and ash 2020 news |
| publisher |
IP Habib O.N. |
| publishDate |
2021 |
| url |
https://doaj.org/article/772208517a7b4f479036d2979c08965d |
| work_keys_str_mv |
AT elenaademina hodgkinlymphomaascoehaandash2020news |
| _version_ |
1718406451944226816 |